Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase III Randomized Open-Label Multi-centre Study of Ruxolitinib versus best available therapy in patients with Corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
Protocol ID
REACH2
Disease (Sub Disease)
Corticosteroid Refractory Acute Graft vs Host Disease
Diagnosis Stage
Previously treated
Sponsor
Novartis Pharmaceuticals
Links
Trial Status
Completed
Trial Close Date
23/04/2021
Study Type
Parallel Assignment
Phase
Phase 3
Age Eligibility
12 Years and older
International registry ID's
NCT02913261
| Study Title | A Phase III Randomized Open-Label Multi-centre Study of Ruxolitinib versus best available therapy in patients with Corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation |
|---|---|
| Protocol ID | REACH2 |
| Disease (Sub Disease) | Corticosteroid Refractory Acute Graft vs Host Disease |
| Diagnosis Stage | Previously treated |
| Sponsor | Novartis Pharmaceuticals |
| Links | https://clinicaltrials.gov/ct2/show/NCT02913261 |
| Trial Status | Completed |
| Trial Open Date | 10/03/2017 |
| Trial Close Date | 23/04/2021 |
| Study Type | Parallel Assignment |
| Phase | Phase 3 |
| Age Eligibility | 12 Years and older |
| International registry ID's | NCT02913261 |